Brazil said Monday that it had halted a late-stage trial of a Chinese vaccine that had been considered a global front-runner in the race to develop a protective shot for the coronavirus, after a “serious adverse” reaction in a participant.
The Brazilian health regulator provided little information on its decision, including whether the reaction was related to the vaccine, called CoronaVac and produced by the Chinese company Sinovac, or coincidental.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.